Literature DB >> 3316575

Renal transplantation without steroids.

J R Salaman1, C A Gomes Da Costa, P J Griffin.   

Abstract

In a randomized, controlled clinical trial, patients undergoing renal transplantation received as immunosuppression either cyclosporine alone (15 to 17 mg/kg) or cyclosporine with prednisolone, 0.3 mg/kg/d. The patients were followed up for 2 to 4 years, but no differences in the survival rates of patients or their transplants were seen. The survival of first cadaver grafts after 1 year was 73% and 76% in groups receiving cyclosporine alone and cyclosporine plus steroids, respectively. Although the patients treated with cyclosporine alone were more susceptible to nephrotoxic effects, the group receiving steroids were significantly more at risk of developing a cushingoid appearance and had an increased incidence of serious infections. After this trial, an additional 45 patients received only cyclosporine, 8 to 10 mg/kg/d, after renal transplantation. Nephrotoxic effects were much less common, and the actuarial survival rate for first cadaver grafts was 83% at 1 year. It is our view that combinations of immunosuppressive agents for kidney transplantation are both unnecessary and possibly harmful and that excellent patient and graft survival rates may be obtained with cyclosporine alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316575     DOI: 10.1016/s0022-3476(87)80050-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

2.  Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients.

Authors:  Troels K Bergmann; Nicole M Isbel; Remo Ostini; Katherine A Barraclough; Scott B Campbell; Brett C McWhinney; Warrick J Inder; Anthony Russell; Christine E Staatz
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 3.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

4.  The timing of introduction of pharmaceutical innovations in seven European countries.

Authors:  Ragnar Westerling; Marcus Westin; Martin McKee; Rasmus Hoffmann; Iris Plug; Grégoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; José L Alfonso; Johan P Mackenbach
Journal:  J Eval Clin Pract       Date:  2014-04-22       Impact factor: 2.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.